Pfizer Sees Unusually High Options Volume (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) was the recipient of unusually large options trading activity on Thursday. Traders purchased 254,818 call options on the stock. This is an increase of approximately 84% compared to the typical volume of 138,504 call options.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.05 during trading on Thursday, reaching $26.48. The stock had a trading volume of 48,216,503 shares, compared to its average volume of 42,952,375. Pfizer has a 52 week low of $21.97 and a 52 week high of $28.75. The business’s 50-day moving average price is $27.16 and its 200 day moving average price is $26.14. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock has a market capitalization of $150.56 billion, a PE ratio of 20.21 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.48%. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the company posted $0.92 earnings per share. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer will post 2.97 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently modified their holdings of PFE. Horizon Financial Services LLC increased its holdings in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. HFM Investment Advisors LLC increased its holdings in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. increased its holdings in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 results beat and guidance reaffirmed — Pfizer reported Q1 revenue of $14.45B and EPS of $0.75 (both above expectations) and reaffirmed FY26 guidance, supporting the view that newer medicines are offsetting COVID-era declines. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Oncology momentum — recent milestones include FDA approval of VEPPANU (first PROTAC degrader approval) and positive Phase 3 data for ELREXFIO in multiple myeloma, which materially strengthen Pfizer’s oncology franchise and longer-term growth narrative. Pfizer Oncology Advances Raise New Questions For Valuation And Momentum
• Positive Sentiment: Dividend durability — coverage pieces argue Pfizer’s ~6.5% yield is sustainable after management commentary and results, reducing fears of a yield trap and supporting income-focused buyers. Pfizer’s 6.5% Dividend Yield Looked Too Good to Be True — but Management Just Silenced the Skeptics
• Neutral Sentiment: Lyme vaccine update — Pfizer is running an extra/fifth-dose VLA15 trial; the move signals continued investment in the program but creates uncertainty on final labeling/dosing and commercial timing. Pfizer’s Next Lyme Shot: What a Fifth-Dose VLA15 Trial Signals for PFE Investors
• Neutral Sentiment: Share-shelf / employee offering noted — Pfizer filed a large employee share offering shelf registration (~$8.4B referenced in coverage). That supports compensation/liquidity plans but raises watchfulness for potential dilution. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Neutral Sentiment: Analyst views mixed — recent coverage shows conflicting analyst sentiments on valuation and momentum; this contributes to choppy intraday trading as investors sort thesis changes. Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Compass Therapeutics (CMPX)
• Negative Sentiment: Trial termination trims oncology upside — Pfizer ended a Phase 1b/2 lymphoma combo trial, which reduces near-term clinical-option value in that program and tempers some enthusiasm about oncology pipeline expansion. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PFE. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. Barclays assumed coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.74.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.